Caliper Wraps Up NovaScreen Acquisition
Caliper Life Sciences has completed its acquisition of NovaScreen Biosciences for up to $30 million, the companies said last week.
Caliper can now set its sights on the outsourced assay-development and -screening markets, "especially" the secondary screening and profiling -services market, the company said in a statement. The acquisition could also enable Caliper to play a greater role in the kinase-screening market.
As CBA News reported last month, Caliper Life Sciences planned to acquire NovaScreen for $22 million, subject to certain financial parameters, and up to an additional $8 million, depending on revenue milestones over the next 30 months (see CBA News, 9/12/2005). Eighty percent of the payments will be made in Caliper common stock and 20 percent in cash.
Caliper said it expects NovaScreen to contribute approximately $2 million to its revenues.
Hanover, Md.-based NovaScreen focuses on in vitro screening assays and in silico predictive screening tools, with particular expertise in receptor pharmacology.
Celliance Acquires Gene-Expression Technology from Innovata
Celliance has acquired a gene-expression technology from Innovata for an undisclosed amount, the wholly owned Serologicals subsidiary said last week.
The so-called ubiquitous chromatin opening element technology allows researchers to improve the yield, consistency, and stability of protein production in cultured mammalian cells. Other applications include gene therapy, transgenics, and the generation of cell lines for drug screening, according to Celliance.
The technology has been licensed by a number of pharmaceutical and biotechnology companies, including Medarex and Maxygen.
PerkinElmer, Divesting Three Units, Shifts Focus on Health Sciences, Photonics
PerkinElmer will shift its strategic focus on the health sciences and photonic markets by selling its aerospace, semiconductor, and fluid-testing businesses, the company said last week.
"The proceeds will help us build our growth platforms, with particular emphasis on genetic screening, medical imaging, molecular medicine, and service," PE chairman and CEO Gregory Summe said in a company statement.
PE will sell its aerospace business to Eaton for approximately $333 million, and is in discussions to sell its semiconductor and fluid testing businesses by the end of the year. The company said it expects to gain approximately $400 million from the sale of the Fluid Sciences business alone.